|
Video: What is a Stock Split?
|
|
Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux (GERD) disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Co.'s lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a noninvasive office procedure, serving as a screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. According to our Lucid Diagnostics stock split history records, Lucid Diagnostics has had 0 splits. | |
|
Lucid Diagnostics (LUCD) has 0 splits in our Lucid Diagnostics stock split history database.
Looking at the Lucid Diagnostics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lucid Diagnostics shares, starting with a $10,000 purchase of LUCD, presented on a split-history-adjusted basis factoring in the complete Lucid Diagnostics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/15/2021 |
|
End date: |
05/02/2024 |
|
Start price/share: |
$9.35 |
|
End price/share: |
$0.95 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-89.84% |
|
Average Annual Total Return: |
-59.24% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,016.01 |
|
Years: |
2.55 |
|
|
|
|
|